By Fineline Cube Youcare Pharmaceutical (SHA: 688658) announced that its investigational compound YKYY033 has received clinical trial approval from China’s National Medical Products Administration (NMPA) for multiple new indications spanning thrombotic and cardiovascular disorders. The RNA interference (RNAi) therapeutic targets coagulation Factor XI (FXI) and represents a novel approach to anticoagulation with potentially improved safety profiles.
Clinical Trial Indications Approved
| Therapeutic Area | Specific Indications |
|---|---|
| Venous Thromboembolism | • Treatment of deep vein thrombosis (DVT) in adults • Reduction of recurrent DVT and pulmonary embolism (PE) following acute DVT • Treatment and secondary prevention of cancer-associated venous thromboembolism (VTE) |
| Cardiovascular | • Reduction of stroke and systemic embolism risk in non-valvular atrial fibrillation (NVAF) • Reduction of major cardiovascular events in chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) |
| Renal | • Prevention of major thrombotic vascular events in end-stage renal disease (ESRD) |
Drug Profile & Mechanism of Action
- Compound: YKYY033
- Class: Chemically synthesized double-stranded siRNA drug
- Delivery System: Conjugated with N-acetylgalactosamine (GalNAc) ligand for hepatocyte-specific targeting
- Development: Independently developed by Youcare Pharmaceutical and Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Mechanism: Utilizes RNA interference (RNAi) to effectively silence messenger RNA (mRNA) transcribed from the coagulation Factor XI (FXI) gene
- Therapeutic Effect: Inhibits production of FXI protein, a key component in the intrinsic coagulation pathway
Scientific Rationale
Targeting Factor XI offers a potentially safer anticoagulation strategy compared to traditional approaches:
- Reduced Bleeding Risk: FXI inhibition may provide effective antithrombotic activity while preserving hemostasis, potentially minimizing bleeding complications
- Broad Applicability: Single mechanism addresses multiple thrombotic conditions across different patient populations
- Novel Target: Represents next-generation anticoagulation beyond vitamin K antagonists and direct oral anticoagulants (DOACs)
Development Partnership
The collaboration between Youcare Pharmaceutical (SHA: 688658) and Hangzhou Tianlong Pharmaceutical leverages complementary expertise in RNAi therapeutics and cardiovascular drug development. This partnership accelerates clinical advancement through shared resources and specialized capabilities.
Market Opportunity
The approved indications represent substantial commercial potential:
- Atrial Fibrillation: Affects over 46 million people globally with significant stroke risk
- Venous Thromboembolism: Annual incidence of 1-2 per 1,000 individuals in developed countries
- Coronary Artery Disease: Leading cause of death worldwide with 17.9 million annual fatalities
- Anticoagulation Market: Global market projected to exceed $30 billion by 2030
Strategic Significance
This multi-indication clinical trial approval positions Youcare at the forefront of next-generation anticoagulation therapy. The RNAi approach could address critical unmet needs in patients who cannot tolerate current anticoagulants due to bleeding risks or contraindications.
Company Background
Youcare Pharmaceutical (SHA: 688658) is a Shanghai-listed biopharmaceutical company focused on developing innovative therapeutics for cardiovascular and metabolic diseases. The company’s RNAi platform represents a strategic expansion into nucleic acid-based therapeutics.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial expectations. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech